Kornimate/medical-research-clean huggingface dataset:
rapid strep test results

Conditions: Strept Throat

Summary: this is a prospective study seeks to determine how often a rapid antigens test for group a streptococcus is positive in healthy adults

the unites states recommends the use of rapid antigen tests, but a number of other countries do not, citing a high prevalence of streptococcal carriers and only moderate sensitivity of rapid antigen tests \[1\]. indeed, to fully understand when rapid antigen tests should be used, we need to know the streptococcal carrier rate for adults in the united states. although there is a fair amount of data in this regard for children \[2,3\], the only study to report this value for adults was from over 20 years ago and was from sweden \[4\]. that studied reported a group a streptococcus (gas) carrier rate of 2.4-3.7% in healthy adults. given how many patients seek medical care for sore throats that may potentially be streptococcal pharyngitis, the investigators believe more data about the gas carrier rate and the rate of false positive rapid antigen tests is necessary. thus, the investigators propose a prospective study to evaluate the rate of positive rapid antigen tests in healthy adult patients in our community. the investigators will perform rapid antigen tests for gas on healthy adult subjects without any symptoms. consenting patients will fill out a brief data collection form about their medical history, and an investigator will perform a rapid antigen throat swab to assess for gas. the results of the rapid antigen test will be recorded, and a logistic regression analysis will be performed to determine if certain factors within the subject's medical history are predictive of positive rapid strep tests.

Eligibility criteria:
inclusion criteria: * any person at least 18 years old exclusion criteria: * pregnant * prisoners * currently taking antibiotics * any acute symptoms

Keywords: carrier rate rapid antigen test
focal therapy for localised prostate cancer using irreversible electroporation

Conditions: Prostate Cancer

Summary: to determine the adverse events and genito-urinary side-effect profile of focal therapy to treat localised low to intermediate risk prostate cancer using irreversible electroporation (nanoknife™).


Eligibility criteria:
inclusion criteria: * histologically proven prostate cancer, gleason score \</=7 * an anterior visible lesion on mpmri, that is accessible to ire treatment * transperineal prostate biopsies (template mapping and/or limited targeted) correlating with clinically significant lesion in the area of the mr-visible lesion (within 2 barzell zones) * absence of clinically significant disease outside of the planned treatment zone, from histopathology and/or mpmri findings * stage radiologicalt1-t2cn0m0 disease, as determined by local guidelines * serum psa \</=15 ng/ml * life expectancy of \>/= 10 years * signed informed consent by patient * an understanding of the english language sufficient to understand written and verbal information about the trial and consent process exclusion criteria: * men who have had previous radiation therapy * men who have had androgen suppression/hormone treatment within the previous 12 months for their prostate cancer * men with evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging * men with a non-visible tumour on mpmri * men with an inability to tolerate a transrectal ultrasound * men with latex allergies * men who have undergone prior significant rectal surgery preventing insertion of the trus probe (decided on the type of surgery in individual cases) * men who have had previous ire, hifu, cryosurgery, thermal or microwave therapy to the prostate. * men who have undergone a transurethral resection of the prostate (turp) for symptomatic lower urinary tract symptoms within 6 months. these patients may be included within the trial if deferred from consenting and screening until at least 6 months following the turp. * men not fit for major surgery as assessed by a consultant anaesthetist * men unable to have pelvic mri scanning (severe claustrophobia, permanent cardiac pacemaker, metallic implant etc likely to contribute significant artefact to images) * presence of metal implants/stents in the urethra * men with renal impairment with a gfr of \<35ml/min (unable to tolerate gadolinium dynamic contrast enhanced mri).

Keywords: focal therapy
a study to investigate the effects of act-541468 on nighttime respiratory function in patients with mild to moderate obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: this study is conducted to investigate the effects of act-541468 on nighttime respiratory function in patients with mild to moderate obstructive sleep apnea


Eligibility criteria:
inclusion criteria: * signed informed consent in a language understandable to the subject prior to any study-mandated procedure. * male and female subjects aged ≥ 18 years at screening. * women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at screening visit 2 and on day 1 pre-dose of the first period. they must agree to consistently and correctly use a highly effective method of contraception with a failure rate of \< 1% per year. * women of non-childbearing potential, i.e., postmenopausal, with previous bilateral salpingectomy, bilateral salpingo-oophorectomy or hysterectomy, or with premature ovarian failure, xy genotype, turner syndrome, and/or uterine agenesis. * diagnosis of osa according to the international classification of sleep disorders documented by medical history and confirmed in a sleep laboratory in the context of diagnosing osa within the last 3 years. * patient with mild to moderate intensity of osa determined during osa diagnosis and confirmed on the screening night psg and defined as apnea/hypopnea index (ahi) ranging from 5 to \< 30. exclusion criteria: * any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol. * pregnant or lactating women. * modified swiss narcolepsy scale total score \< 0 at screening, or history of narcolepsy or cataplexy. * subjects with clinically significant abnormality on the screening night psg as per investigator judgment, including evidence of severe insomnia (i.e., sleep time \< 5 h) periodic limb movement disorder with arousal index ≥ 10/h, restless legs syndrome, circadian rhythm disorder, rem behavior disorder, parasomnia including nightmare disorder, sleep terror disorder, and/or sleepwalking disorder. * need for continuous positive airway pressure device or a dental appliance device within the preceding 7 days prior to screening visit 2 and during the course of the study, i.e., from screening visit 2 to eos. * evidence of any other clinically significant active pulmonary disease such as chronic obstructive pulmonary disease (copd) (as per global initiative for obstructive lung disease), based on investigator's judgment. * history of surgical intervention for obstructive sleep apnea, except nose surgery. * sao2 \ 5 consecutive min during the screening night psg.
can additional drug therapy accelerate response time to antidepressants

Conditions: Depression

Summary: antidepressants are commonly prescribed and are effective for treating depression. however, they generally take 4-6 weeks for a therapeutic response. this study is evaluating whether simultaneous treatment with thyroid hormone or pindolol can decrease the response time ("getting better faster") in patients who are starting ssri treatment.

major depression is an illness with substantial personal and economic morbidity (greenberg et al.1993) and antidepressants are the cornerstone of treatment. as antidepressants usually require 3-6 weeks of use before a response occurs, an effective antidepressant acceleration strategy would reduce the time of onset for an effective antidepressant response. this has significant clinical implications, as it could lead to reduced symptom morbidity, potentially reduce health care cost (i.e. shorter hospital length of stay), and improve functional capacity and quality of life. the goal of this study is to enhance our understanding of strategies that accelerate or produce a more rapid treatment response in depression. this could lead to reduced symptom morbidity, potentially reduce health care cost (i.e. shorter hospital length of stay), and improve functional capacity and quality of life. the study goals are: 1.) to assess whether the simultaneous commencement of liothyronine or pindolol to an ssri can accelerate the treatment response (i.e. faster rate of improvement), 2.) to assess whether the simultaneous commencement of liothyronine or pindolol to an ssri can augment or enhance treatment response (i.e. greater reduction in depressive symptoms at end of study phase), adn 3.) to assess whether gender influences the acceleration of augmentation response rate of liothyronine or pindolol.

Eligibility criteria:
inclusion criteria: 1. patients, male and female, between the ages of 18 to 65 2. dsm-iv criteria for major depressive disorder 3. no prior ssri medication treatment (if a patient has discontinued a non-ssri medication for side effects, they will not be excluded) 4. ability to be followed clinically for 6 weeks 5. each patient must understand the nature of the study and must sign an informed consent form exclusion criteria: 1. severe suicidality (as defined by beck depression inventory question 9, responses 2 or 3) 2. major axis i mental illness other than major depressive disorder 3. unstable medical health specifically cardiovascular disease, abnormal ekg, history of severe drug allergy, poorly controlled diabetes, and asthma (pindolol contraindication) 4. history of thyroid disease or abnormal tft's (stage i or ii) 5. need for adjunctive antipsychotic use or additional benzodiazepine during the study 6. pregnancy 7. seizure disorder 8. a positive urine toxicology screen

Keywords: depression
screening epidemiological program on compensation evaluation of diabetes mellitus type 2 (dmt2) patients on oral anti-diabetic (oad) monotherapy and physicians satisfaction of their usage

Conditions: Type 2 Diabetes

Summary: the purpose of the study is assessment of glycemic control and physicians satisfaction with results of dm2 oad monotherapy


Eligibility criteria:
inclusion criteria: * patients have an established diagnosis of t2d * experience of therapy with one oad during the from 6 months to 5 years before the registration in the program exclusion criteria: * experience of therapy with two or more oads and/or insulin therapy and/or incretin mimetics (exenatide) at any time before registration in the program * absence of changes in hbac1 level during the last year before registration in the program

Keywords: type 2 diabetes
impact of qsofa calculation on the timing of antimicrobial therapy in the emergency department

Conditions: Bacterial Infection; Intensive Care

Summary: the delayed administration of an adequate antimicrobial therapy is a strong predictor of impaired outcome in patients with bacterial sepsis. therefore, the current surviving sepsis campaign guidelines (2016) recommend that administration of intravenous antimicrobials be initiated within one hour following the recognition of sepsis or septic shock. the quick sepsis-related organ failure assessment (qsofa) score is a new bedside tool which has been recently proposed by the third international sepsis consensus definitions task force (sepsis-3) to identify patients with suspected infection who are at greater risk for a poor outcome outside the intensive care unit (icu). it uses three criteria, assigning one point for low systolic blood pressure (sbp ≤100 mmhg), high respiratory rate (≥22 breaths per min) and altered mentation (glasgow coma scale \<15). the score ranges from 0 to 3 points. a qsofa value ≥2 points is associated with a greater risk of death or prolonged icu stay, these outcomes being more common in infected patients who may be septic than in those with uncomplicated infection. the definite goal of qsofa is to hasten the management and thus improve the outcome of patients at risk of sepsis or septic shock. many patients admitted to the hospital for bacterial sepsis or septic shock are initially managed in the emergency department (ed). this study aims at investigating whether the routine calculation of qsofa at patient triage may hasten the initiation of antimicrobial therapy in patients admitted to the ed with suspected or proven bacterial infection, especially in those with subsequent criteria for sepsis or septic shock (sepsis-3 definition).


Eligibility criteria:
inclusion criteria: • suspected or proven bacterial infection at emergency department triage exclusion criteria: * imminent death * pregnancy * breast-feeding * for patients managed by a medicalized pre-hospital emergency team before ed admission : administration of a first dose of antimicrobial agent before ed admission * lack of coverage by the public health insurance system * patient's refusal for study enrollment * lack of confirmed bacterial infection (i.e., documented either clinically, microbiologically or by imaging procedures) in patients with a suspected bacterial infection at emergency departement triage

Keywords: sepsis shock, septic emergency service, hospital anti-infective agents outcome assessment
msi-78 topical cream vs. oral ofloxacin in the treatment of infected diabetic ulcers

Conditions: Diabetic Foot Ulcers

Summary: 224 adults with diabetic foot ulcers will be randomized to either magainin peptide (msi-78) or ofloxacin (floxin, ortho-mcneil pharmaceutical corporation) an oral fluoroquinolone antibiotic.

approximately 224 adults will be enrolled in an outpatient phase iii study to compare the safety and efficacy of topically applied magainin peptide (msi-78) to that of ofloxacin (floxin, ortho-mcneil pharmaceutical corporation) an oral fluoroquinolone antibiotic, in the treatment of infected diabetic foot ulcers. this is a randomized, controlled, double-blind trial that will involve twenty or more clinical centers.

Eligibility criteria:
inclusion criteria: * non-hospitalized ambulatory patients with diabetes mellitus * men or women greater than 18 years old * patients must be considered reliable, willing and able to give consent * female patients must be postmenopausal for a least 6 months or surgically sterilized * localized infection of the ulcer that would ordinarily be treated on an outpatient basis * patients who have been previously treated or are currently under treatment for a localized infections of an ulcer may be enrolled in there has been an adequate response to treatment and ulcer is still infected * patient must have radiograph within two weeks of entry showing no evidence of cortical destruction consistent with osteomyelitis * patient must have a palpable dorsalis pedis or posterior tibial pulse in the affected foot * patient may not be taking or have received any other investigational therapy or approved therapy within 30 days prior to entry exclusion criteria: * patients requiring concurrent local or systemic antimicrobials during the study period for other infections * patients who are currently treated or awaiting dialysis * patients who are unable to care for their ulcers * patients with known alcohol or substance abuse within 6 months or study entry * patients with significant gi problems or surgery that might interfere with the absorption of ofloxacin * patients who are currently receiving systemic corticosteroids, immunosuppressives, antivirals, radiation therapy or cytotoxic agents * patients who currently require treatment or a primary or metastatic malignancy or have systemically immunocompromising disease. * previous enrollment in this study or previous treatment with msi-78 topical cream * patients with gangrene or severely impaired arterial supply to any portion of the affected foot * other conditions considered by the investigator to be sound reason for disqualification * patients with any known allergy to ofloxacin, other quinolone antibiotics, magainin peptides or ingredients of the vehicle cream * women who are breast feeding, pregnant or attempting to become pregnant

Keywords: diabetic diabetes mellitus foot ulcers floxin oral antibiotic topical cream
optimized water vapor thermal therapy for benign prostatic hyperplasia

Conditions: Benign Prostatic Hyperplasia

Summary: water vapor thermal therapy (rezum) is a minimally invasive treatment for benign prostatic hyperplasia (bph) that uses injections of sterile water vapor directly into the prostate for tissue ablation.

for bph, open or transurethral anatomical enucleation is recommended. open prostatectomy has a higher risk of bleeding and slower postoperative recovery, with a higher probability of requiring blood transfusion. the incidence of urinary incontinence after transurethral enucleation ranges from 3.33% to 20%, possibly due to excessive traction and compression on the external urethral sphincter, leading to partial muscle fiber rupture. the rate of erectile dysfunction after enucleation is 8.82%, while retrograde ejaculation occurs in 6.37% of cases, especially for patients with larger prostates. once these complications occur, they are often difficult to recover from and severely impact the patient's quality of life. in our center, the technique of rezum has been further improved by incorporating ultrasound and mri imaging guidance. the investigators design a reasonable and comprehensive ablation plan that ensures accurate positioning of enlarged prostate glands for complete and thorough ablation while ensuring efficacy and safety. the optimized methods mainly include ablation optimization and combined imaging techniques.

Eligibility criteria:
inclusion criteria: 1. male subjects ≥ 45 years of age who have obstructive symptoms secondary to bph requiring invasive intervention. 2. ipss score of ≥ 13. 3. qmax: peak flow rate ≤ 15 ml/sec. 4. post-void residual (pvr) \< 300 ml. 5. prostate volume \> 30 ml. 6. subject able to complete the study protocol in the opinion of the principal investigator. exclusion criteria: 1. history of any illness or surgery that in the opinion of the principal investigator may confound the results of the study. 2. any prior minimally invasive intervention or surgical intervention for the symptoms of bph. 3. currently enrolled in another clinical trial. 4. confirmed or suspected malignancy of prostate or bladder. 5. documented active urinary tract infection by culture or bacterial prostatitis. 6. neurogenic bladder or sphincter abnormalities. 7. urethral strictures, bladder neck contracture or muscle spasms. 8. bleeding disorder (note that use of anti-platelet medication is not an exclusion criterion). 9. subjects who are interested in maintaining fertility. 10. significant urge incontinence. 11. unable or unwilling to sign the informed consent form. 12. any cognitive disorder that interferes with or precludes a subject from directly and accurately communicating with the principal investigator regarding the study.
shortened depression assessment study

Conditions: Depression

Summary: participants will be asked to fill out an online questionnaire about their demographics information and all 42 items from the depression anxiety stress scale (dass-42). a series of machine learning techniques will be applied to the dataset to develop a shortened assessment using the most important demographics and dass-42 items from the original questionnaire, to predict depression levels indicated by dass-42.

clinical depression affects 5-10% of the world population each year and is a serious mental health issue globally. there are many traditional psychological scales that assess levels of depression in adults, where their items are often redundant in the information they carry, and their scoring is not necessarily linear to the item scores. thus, machine learning techniques can help find the redundancy in the items, as well as the nonlinear relationship between the item scores and the final prediction. using the depression anxiety stress scale 42 (dass-42) as the basis, participants will be asked to fill out an online questionnaire about their demographics information (age, gender, country of residence, race, etc.) and all 42 items of dass-42 to provide a dataset for this study. feature selection techniques such as mrmr and gini feature importance were applied to identify the most important features in the dataset. then, using machine learning methods such as logistic regression, xgboost, and ensemble models, models will be fitted on the most important features to develop a shortened depression scale (7-9 items consisting of demographics items and dass items) that accurately predicted the levels of depression (as measured by the auc, roc and f1 scores.

Eligibility criteria:
inclusion criteria: * adults aged 18 and above * must be able to read english * must have access to the internet worldwide exclusion criteria: * children aged 17 and under * persons who cannot read english * persons that do not have access to internet

Keywords: depression moderate depression severe survey methodology
lung herniation after uniportal vats

Conditions: Lung Hernia; Thoracoscopy; Postoperative

Summary: during patient follow up the investigators noticed the occasional occurence of a lung herniation after uniportal video assisted thoracoscopic surgery (vats). most of these patients were asymptomatic and didn't require any kind of treatment. to analyse the incidence of postoperative lung herniation after uniportal and the presence of symptoms the investigators decided to review every postoperative ct scan from january 2016 until march 2019 to radiologically identify postoperative lung herniations. afterwards the investigators will contact the respective patient to ask for a follow-up physical examination and symptom evaluation (after consent was signed).


Eligibility criteria:
inclusion criteria: * anatomical lung resection using uniportal vats exclusion criteria: * non anatomical lung resection * open surgery * pneumonectomy * informed consent not signed
serrantor oct study

Conditions: Critical Limb Ischemia

Summary: ta prospective randomized control trial to evaluate the serration angioplasty effect in btk arteries with varying degrees of calcified plaque.


Eligibility criteria:
inclusion criteria: * rutherford clinical category 4-6 of the target limb * age of subjects is \>18 years old * patients has given informed consent to participate in this study exclusion criteria: * de novo or restenotic (without prior stent) stenosis (≥70%) or occlusion * target lesion is in the btk arteries, including below the knee popliteal, tibioperoneal trunk, tibial, peroneal, and pedal arteries. * angiographic visual estimated reference vessel diameter is between 2.0 and 5.0 mm. * lesion length less than 220 mm